Skip to main content
. 2022 Apr 22;3(5):100631. doi: 10.1016/j.xcrm.2022.100631

Figure 3.

Figure 3

Adverse events correlate with neutralizing antibodies

(A) Heatmap representation of Spearman correlation matrix between symptom severity scores and antibody responses (primary vaccination). n = 92.

(B and C) RBD IgG (B) and NT titers (C) were evaluated based on the local symptom severity scores after primary vaccination. 0, n = 15; 1–2, n = 65; ≥3, n = 12.

(D and E) RBD IgG (D) and NT titers (E) were evaluated based on the systemic symptom severity scores after primary vaccination. 0, n = 40; 1–4, n = 47; ≥5, n = 5.

(F) Heatmap representations of Spearman correlation matrix between symptom severity scores and antibody responses (secondary vaccination). n = 92.

(G and H) RBD IgG (G) and NT titers (H) were evaluated based on the local symptom severity scores after secondary vaccination. 0, n = 11; 1–2, n = 56; ≥3, n = 25.

(I and J) RBD IgG (I) and NT titers (J) were evaluated based on the systemic symptom severity scores after secondary vaccination. 0, n = 15; 1–4, n = 39; ≥5, n = 38.

(K) Heatmap representations of Spearman correlation matrix between symptom severity scores and cytokine dynamics (d22–d21 post/pre ratios). n = 92. Data are shown as the median and points indicate each participant in (B–E). Statistical significance is indicated as follows; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, Spearman’s rank-order coefficient test in (A, F, and K); Kruskal-Wallis test in (B–E, G–J). Spearman’s r values are indicated in each cell in (A, F, and K).